About
Mendaera is a medical robotics company redefining how clinicians perform needle-based procedures through its flagship product, the Focalist™ Handheld Robotic System. Ultrasound-guided procedures demand years of mastery—precise needle targeting under real-time imaging is a demanding skill prone to variability. Mendaera addresses this challenge by merging handheld robotics with live ultrasound imaging, providing real-time positional guidance that helps clinicians place instruments accurately relative to the ultrasound transducer and resulting image. The Focalist system received FDA clearance and is designed for use with both pediatric and adult patients across diagnostic and therapeutic procedures. By mechanically stabilizing and guiding needle trajectories, it dramatically reduces the learning curve and cognitive burden placed on clinicians, enabling more providers to perform high-precision interventional work with confidence. Mendaera has been recognized by Bessemer Venture Partners among the Top 50 startups transforming industries with physical AI, underscoring the company's position at the frontier of AI-assisted robotics in healthcare. The system is preparing for a broad commercial launch in 2026, with early access available for interested healthcare institutions. Mendaera's technology is particularly relevant for interventional radiology, anesthesiology, emergency medicine, and any clinical setting where ultrasound-guided needle placement is performed.
Key Features
- Handheld Robotic Guidance: The Focalist™ system provides robotic stabilization and trajectory guidance in a handheld form factor, making precision needle placement accessible without large stationary robotic infrastructure.
- Real-Time Ultrasound Integration: Integrates directly with ultrasound imaging to position instruments relative to the transducer and live image, giving clinicians continuous visual and mechanical feedback during procedures.
- FDA Clearance for Broad Patient Use: Cleared by the FDA for diagnostic and therapeutic needle-based procedures in both pediatric and adult patients, meeting rigorous regulatory standards for clinical safety and efficacy.
- Reduced Skill Barrier: Lowers the years-long learning curve traditionally required for ultrasound-guided procedures, enabling more clinicians to perform high-precision interventions confidently.
- Physical AI Innovation: Recognized among the top physical AI startups transforming industries, Focalist merges robotics and AI-driven imaging guidance into a practical clinical tool.
Use Cases
- Interventional radiologists performing ultrasound-guided biopsies or drain placements with improved needle trajectory accuracy
- Anesthesiologists conducting nerve blocks or regional anesthesia procedures requiring precise needle targeting near anatomical structures
- Emergency medicine physicians performing ultrasound-guided vascular access or thoracentesis in high-pressure clinical environments
- Hospitals seeking to expand the number of clinicians qualified to perform advanced ultrasound-guided procedures by lowering the skill barrier
- Academic medical centers and teaching hospitals integrating robotic guidance tools to train the next generation of proceduralists
Pros
- FDA Cleared: Full regulatory clearance provides healthcare institutions with confidence in clinical safety and opens the path to broad adoption across hospitals and clinics.
- Democratizes Advanced Procedures: By reducing the skill threshold for ultrasound-guided needle placement, more clinicians can perform procedures that previously required years of specialized training.
- Handheld Form Factor: Unlike bulky robotic surgical systems, the Focalist's handheld design integrates naturally into existing clinical workflows without requiring major infrastructure changes.
- Pediatric and Adult Coverage: Cleared for use across patient populations including children, broadening the potential impact across diverse clinical settings.
Cons
- Not Yet Broadly Available: The commercial launch is planned for 2026, so most healthcare providers cannot yet access or deploy the system at scale.
- Limited to Needle-Based Procedures: The Focalist system is purpose-built for ultrasound-guided needle placement and is not a general-purpose robotic surgical platform.
- Physician Prescription Required: As a regulated medical device, federal law restricts sale to licensed physicians, limiting direct access outside of clinical settings.
Frequently Asked Questions
What is the Mendaera Focalist™ system?
The Focalist™ is the world's first FDA-cleared handheld robotic system designed to guide clinicians in performing ultrasound-guided needle-based procedures with greater precision and confidence.
Has the Focalist system received FDA clearance?
Yes. Mendaera received FDA clearance for the Focalist™ system, and the company is preparing for a broad commercial launch in 2026.
Who is the Focalist system designed for?
It is designed for licensed physicians and clinicians who perform interventional procedures requiring precise needle placement under ultrasound imaging, such as in radiology, anesthesiology, or emergency medicine.
Can the Focalist be used with pediatric patients?
Yes. The system is cleared for use with both pediatric and adult patients in diagnostic and therapeutic procedures.
When will the Focalist system be commercially available?
Mendaera is preparing for a broad commercial launch in 2026. Healthcare providers can sign up on the Mendaera website to receive exclusive updates and early access information.
